Details

Autor(en) / Beteiligte

• Levi, Izhak
• Gurevich, Michael
• Perlman, Gal
• Magalashvili, David
• Menascu, Shay
• Bar, Noam
• Godneva, Anastasia
• Zahavi, Liron
• Chermon, Danyel
• Kosower, Noa
• Wolf, Bat Chen
• Malka, Gal
• Lotan-Pompan, Maya
• Weinberger, Adina
• Yirmiya, Erez
• Rothschild, Daphna
• Leviatan, Sigal
• Tsur, Avishag
• Didkin, Maria
• Dreyer, Sapir
• Eizikovitz, Hen
• Titngi, Yamit
• Mayost, Sue
• Sonis, Polina
• Dolev, Mark
• Stern, Yael
• Achiron, Anat
• Segal, Eran

Titel

Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis

Ist Teil von

• Cell reports. Medicine, 2021-04, Vol.2 (4), p.100246-100246, Article 100246

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Multiple sclerosis (MS) is an immune-mediated disease whose precise etiology is unknown. Several studies found alterations in the microbiome of individuals with MS, but the mechanism by which it may affect MS is poorly understood. Here we analyze the microbiome of 129 individuals with MS and find that they harbor distinct microbial patterns compared with controls. To study the functional consequences of these differences, we measure levels of 1,251 serum metabolites in a subgroup of subjects and unravel a distinct metabolite signature that separates affected individuals from controls nearly perfectly (AUC = 0.97). Individuals with MS are found to be depleted in butyrate-producing bacteria and in bacteria that produce indolelactate, an intermediate in generation of the potent neuroprotective antioxidant indolepropionate, which we found to be lower in their serum. We identify microbial and metabolite candidates that may contribute to MS and should be explored further for their causal role and therapeutic potential. [Display omitted] Gut microbiota and metabolites profiles of individuals with MS differ from healthy controlsIndividuals with MS have reduced serum levels of indolepropionateIndividuals with MS have reduced serum levels of indolelactate and its producing bacteriaIndividuals with MS have lower levels of species and genes involved in butyrate production Levi et al. perform a coupled analysis of gut microbiota, untargeted metabolomics, gene expression, nutritional records, and clinical data of individuals with MS. The results suggest that increasing the levels of butyrate-producing species and the levels of the tryptophan metabolites indolepropionate and indolelactate in individuals with MS may have potential benefits.